|
ES3063952T3
(en)
*
|
2015-05-18 |
2026-04-21 |
Agensys Inc |
Antibodies that bind to axl proteins
|
|
WO2016187354A1
(en)
*
|
2015-05-18 |
2016-11-24 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
US20180128545A1
(en)
|
2016-11-08 |
2018-05-10 |
Berry Metal Company |
Modular furnace cooling wall
|
|
CA3131096A1
(en)
|
2019-04-05 |
2020-10-08 |
Chi-Huey Wong |
Sialidase-resistant saccharide and method of making and using the same
|
|
AU2021225827B2
(en)
*
|
2020-02-24 |
2024-12-19 |
Institute Of Microbiology, Chinese Academy Of Sciences |
Humanized monoclonal antibody for 2019 novel coronavirus and use thereof
|
|
WO2021195418A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
|
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
CA3182526A1
(en)
|
2020-05-08 |
2021-11-11 |
Academia Sinica |
Chimeric influenza vaccines
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
PH12022553106A1
(en)
*
|
2020-05-17 |
2023-11-20 |
Astrazeneca Uk Liimited |
Sars-cov-2-antibodies and methods of selecting and using the same
|
|
MX2022014598A
(es)
|
2020-05-26 |
2023-03-31 |
Regeneron Pharma |
Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
|
|
CR20220660A
(es)
|
2020-06-03 |
2023-02-17 |
Regeneron Pharma |
Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
|
|
US20220003779A1
(en)
*
|
2020-07-03 |
2022-01-06 |
The Research Foundation For The State University Of New York |
Methods for qualitative and quantitative analysis of a plurality of biomarkers
|
|
EP4182687A4
(en)
*
|
2020-07-20 |
2024-09-11 |
Bio-Rad Laboratories, Inc. |
IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR
|
|
US20250263468A1
(en)
*
|
2020-07-24 |
2025-08-21 |
Celltrion Inc. |
Binding molecule having neutralizing activity against coronavirus superfamily
|
|
WO2022035918A1
(en)
*
|
2020-08-11 |
2022-02-17 |
Eli Lilly And Company |
Anti-sars-cov-2 antibodies
|
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
PE20231507A1
(es)
*
|
2020-10-02 |
2023-09-26 |
Lilly Co Eli |
Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped
|
|
WO2022082217A1
(en)
|
2020-10-16 |
2022-04-21 |
Eureka Therapeutics, Inc. |
Compositions for preventing or treating viral and other microbial infections
|
|
WO2022162587A1
(en)
*
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
CN115141270A
(zh)
*
|
2021-03-29 |
2022-10-04 |
深圳市康麦生物技术有限公司 |
特异性结合新型冠状病毒的抗体
|
|
WO2022221837A2
(en)
|
2021-04-12 |
2022-10-20 |
Academia Sinica |
Improved coronavirus vaccine
|
|
JP2024518335A
(ja)
*
|
2021-04-26 |
2024-05-01 |
アンスティチュ パスツール |
SARS-CoV-2に対するヒト中和モノクローナル抗体、及びそれらの使用
|
|
CN113461810B
(zh)
*
|
2021-05-17 |
2021-12-28 |
深圳市福田区格物智康病原研究所 |
一种抗新型冠状病毒刺突蛋白的全人源单克隆抗体及其应用
|
|
EP4341289A1
(en)
*
|
2021-05-18 |
2024-03-27 |
Christian-Albrechts-Universität zu Kiel |
Co-stimulatory multispecific antibodies
|
|
CN117897173A
(zh)
*
|
2021-06-08 |
2024-04-16 |
伊莱利利公司 |
含有2019新型冠状病毒抗体的药物制剂
|
|
WO2022263638A1
(en)
*
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
EP4370210A1
(en)
|
2021-07-14 |
2024-05-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
WO2023285620A2
(en)
*
|
2021-07-14 |
2023-01-19 |
Alchemab Therapeutics Ltd. |
Compositions and methods for targeting viral proteins
|
|
US12600764B2
(en)
|
2021-08-27 |
2026-04-14 |
International Business Machines Corporation |
Antigen-binding proteins targeting coronavirus (COV) variants
|
|
CN113735969B
(zh)
*
|
2021-09-20 |
2023-05-12 |
中国人民解放军军事科学院军事医学研究院 |
一种全人源抗新冠病毒广谱高中和活性单克隆抗体及应用
|
|
TW202334429A
(zh)
|
2021-10-01 |
2023-09-01 |
中央研究院 |
Sars-cov-2棘蛋白特異性抗體及其用途
|
|
EP4413122A4
(en)
*
|
2021-10-07 |
2026-04-08 |
Seqirus Pty Ltd |
ANTI-SARS-CoV-2 ANTIBODIES AND THEIR USES I
|
|
US20240425567A1
(en)
*
|
2021-10-08 |
2024-12-26 |
Invivyd, Inc. |
Pharmaceutical formulations comprising anti-coronavirus s protein antibodies and uses thereof
|
|
US20240327505A1
(en)
*
|
2021-10-22 |
2024-10-03 |
University Of Vermont And State Agricultural College |
Antibodies to coronavirus sars-cov-2
|
|
WO2023076419A2
(en)
*
|
2021-10-27 |
2023-05-04 |
Twist Bioscience Corporation |
Sars-cov-2 antibodies and methods of use
|
|
WO2023079137A1
(en)
*
|
2021-11-05 |
2023-05-11 |
Katholieke Universiteit Leuven |
Neutralizing anti-sars-cov-2 human antibodies
|
|
US20250034234A1
(en)
*
|
2021-11-09 |
2025-01-30 |
Rhode Island Hospital |
Predicting covid-19 antibodies among survivors with deep rna sequencing
|
|
WO2023084055A1
(en)
*
|
2021-11-12 |
2023-05-19 |
Rq Biotechnology Limited |
Compositions
|
|
CA3237165A1
(en)
*
|
2021-11-19 |
2023-05-25 |
Jeng-Horng Her |
Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy
|
|
EP4183800A1
(en)
*
|
2021-11-19 |
2023-05-24 |
Medizinische Hochschule Hannover |
Novel sars-cov-2 neutralizing antibodies
|
|
CN116217711A
(zh)
*
|
2021-12-03 |
2023-06-06 |
广东菲鹏生物有限公司 |
一种SARS-CoV-2检测方法和试剂盒
|
|
KR102793620B1
(ko)
|
2021-12-09 |
2025-04-09 |
한국화학연구원 |
사스-코로나바이러스-2 뉴클레오캡시드 단백질에 대한 단클론 항체 및 이의 용도
|
|
WO2023133338A2
(en)
*
|
2022-01-10 |
2023-07-13 |
University Of Pittsburgh – Of The Commonwealth System Of Higher Education |
Molecules that bind to neutrophil elastase polypeptides
|
|
KR20240137083A
(ko)
*
|
2022-01-28 |
2024-09-19 |
에베크 인코포레이티드 |
변이주 교차성을 갖는 항SARS-CoV-2 인간 중화 항체 및 그의 항원 결합성 단편
|
|
US20250145691A1
(en)
*
|
2022-02-15 |
2025-05-08 |
Board Of Regents, The University Of Texas System |
Human monoclonal antibodies targeting the s2 subunit of the sars-cov-2 spike protein
|
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Rq生物科技有限公司 |
抗體
|
|
IL314993A
(en)
|
2022-02-23 |
2024-10-01 |
Xencor Inc |
Anti-cd28 x anti-psma antibodies
|
|
WO2023159316A1
(en)
*
|
2022-02-28 |
2023-08-31 |
Immune Biosolutions Inc. |
Formulation of anti-sars-cov-2 neutralizing antibodies and uses thereof
|
|
US20260035438A1
(en)
*
|
2022-03-04 |
2026-02-05 |
The Scripps Research Institute |
Human broadly neutralizing antibodies against betacoronaviruses
|
|
WO2023178182A1
(en)
*
|
2022-03-16 |
2023-09-21 |
10X Genomics, Inc. |
Compositions and methods for detection and treatment of coronavirus infection
|
|
CN115286712B
(zh)
*
|
2022-03-18 |
2024-09-27 |
北京百普赛斯医学检验实验室有限公司 |
新型冠状病毒Delta突变株特异性抗体及其应用
|
|
WO2023183848A2
(en)
*
|
2022-03-25 |
2023-09-28 |
The Rockefeller University |
Anti-sars-cov-2 antibodies and methods of use thereof
|
|
EP4505179A4
(en)
*
|
2022-04-01 |
2026-06-24 |
Invivyd Inc |
Anti-SARS-CoV-2 antibodies and their uses
|
|
CN114656555B
(zh)
*
|
2022-04-08 |
2024-03-19 |
广州医科大学附属第一医院(广州呼吸中心) |
抗SARS-CoV-2病毒的中和抗体及其制备方法和应用
|
|
EP4508077A4
(en)
|
2022-04-14 |
2026-03-25 |
Invisishield Tech Ltd |
COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS
|
|
CA3256035A1
(en)
|
2022-04-14 |
2023-10-19 |
Invisishield Technologies Ltd. |
COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS
|
|
WO2024025940A1
(en)
*
|
2022-07-26 |
2024-02-01 |
Ap Biosciences, Inc. |
Sars-cov-2 antibodies and bispecific antibodies
|
|
CN116143910B
(zh)
*
|
2022-10-12 |
2026-03-24 |
水木未来(北京)科技有限公司 |
靶向SARS-CoV-2刺突蛋白的纳米抗体及其应用
|
|
KR20250122456A
(ko)
*
|
2022-11-01 |
2025-08-13 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
Fas 리간드에 특이적인 단일클론 항체 및 이의 용도
|
|
WO2024133564A1
(en)
|
2022-12-21 |
2024-06-27 |
National University Of Singapore |
Sars-cov-2 spike protein-binding molecules
|
|
WO2024187177A2
(en)
*
|
2023-03-09 |
2024-09-12 |
The Johns Hopkins University |
Recombinant antibody for the treatment of extracellular dna overload
|
|
CA3268566A1
(en)
|
2023-04-08 |
2024-10-17 |
Rock Biomedical Inc. |
METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
|
|
NZ825394A
(en)
|
2023-04-08 |
2026-03-27 |
Rock Biomedical Inc |
Methods and compositions for dendritic cell targeting nano-delivery
|
|
CN121175414A
(zh)
|
2023-05-17 |
2025-12-19 |
磐石医药生技股份有限公司 |
Mgat1缺乏细胞及其用途
|
|
WO2025222126A1
(en)
*
|
2024-04-19 |
2025-10-23 |
Vanderbilt University |
Var2csa antibodies and methods of use thereof
|
|
WO2025255012A1
(en)
*
|
2024-06-03 |
2025-12-11 |
Uct Bioscience Co., Ltd. |
Anti-grp78 antibody, immunoconjugate and uses thereof
|
|
US20260144885A1
(en)
*
|
2024-11-22 |
2026-05-28 |
Bristol-Myers Squibb Company |
Anti-lrrc15 antibodies and uses thereof
|